Photo

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Photo

Berlusconi's women

A look at the women linked to former Italian Prime Minister Silvio Berlusconi.  Slideshow 

Photo

Harvesting tobacco

With the increasing health concerns with smoking in the U.S., traditional tobacco farmers sell their crop to growing markets outside the country.  Slideshow 

Sponsored Links

Actelion buys U.S.-based firm with cancer drug in development

Related News

A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel, April 23, 2011. REUTERS/Christian Hartmann

A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel, April 23, 2011.

Credit: Reuters/Christian Hartmann

ZURICH | Wed Jul 31, 2013 11:58am EDT

ZURICH (Reuters) - Actelion said it will acquire Ceptaris, a privately held U.S.-based specialty pharmaceutical company developing a topical drug, Valchlor, to treat a form of cancer.

Allschwil-based Actelion said it already paid Ceptaris $25 million and will pay another $225 million when the deal closes. The deal is contingent on Valchlor clinching approval from the U.S. health regulator.

"We expect the transaction to become cash-accretive before the end of 2014," Actelion executive Nicholas Franco said in a statement on Wednesday.

(Reporting By Katharina Bart)

 
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.